Nasal vaccines show new promise for human papillomavirus (HPV) to address cervical cancer and whooping cough. In business news, Korro's stock craters 81% as AATD interim Phase I/II results miss expectations. Additionally, Johnson & Johnson acquires Halda to expand their cancer pipeline while Merck acquires Cidara to boost antivirals. Lastly, the inaugural Genetic Agency Technology Conference (GATC) hosted by Dyno Therapeutics brought together a diverse group of researchers, entrepreneurs, and patient advocates to discuss the mission of genetic agency, or an individual’s ability to take action at the genetic level to live a healthier life.

Join GEN editors Corinna Singleman, PhD, Alex Philippidis, Fay Lin, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news.

Listed below are links to the GEN stories referenced in this episode of Touching Base:

Cervical Cancer May Be Treatable with Intranasal Nanogel Vaccine

GEN, November 15, 2025

Novel Nasal Spray Vaccine for Pertussis Shows Promise

By Corinna Singleman, PhD, GEN, November 12, 2025

StockWatch: Korro Craters 81% on Data; Patient Death Sours Analysts on Intellia

By Alex Philippidis, GENEdge, November 16, 2025

J&J Expands Cancer Pipeline with $3B Halda Acquisition

By Alex Philippidis, GENEdge, November 18, 2025

Merck to Acquire Cidara for $9.2B, Bolstering Antiviral Pipeline

By Alex Philippidis, GEN, November 15, 2025

AI Meets Genetic Agency at Dyno GATC 2025

By Fay Lin, PhD, GENEdge, November 14, 2025

Genetic Agency on Display at GATC 2025

By Kevin Davies, PhD, and Fay Lin, PhD, GEN, November 13, 2025

Dyno GATC Announces AI Agents, Muscle Capsid, and Manufacturing Partner

By Fay Lin, PhD, GEN Edge, November 11, 2025

Touching Base Podcast

Hosted by Corinna Singleman, PhD

Behind the Breakthroughs

Hosted by Jonathan D. Grinstein, PhD

Hosted on Acast. See acast.com/privacy for more information.